Sentinel and Phase IV: A Dilemma For FDA and Industry
This article was originally published in RPM Report
Executive Summary
FDA and industry are both interesting in tapping into Sentinel as an alternative to traditional Phase IV studies. But how can FDA require use of the new capability without having to pay for it?